Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Caribou Biosciences, Inc. (CRBU : NSDQ)

• Company Description    Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in BERKELEY, Calif. Number of Employees: 97

• Price / Volume Information    Yesterday's Closing Price: $2.10 Daily Weekly Monthly 20 Day Moving Average: 1,600,076 shares Shares Outstanding: 99.18 (millions) Market Capitalization: $208.28 (millions) Beta: 2.27 52 Week High: $2.97 52 Week Low: $0.96 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.08% -11.62% 12 Week 5.53% -2.44% Year To Date 32.08% 15.07%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2929 7TH STREET SUITE 105 - BERKELEY,CA 94710 USA ph: 510-982-6030 fax: - investor.relations@cariboubio.com http://www.cariboubio.com

• General Corporate Information    Officers Rachel E. Haurwitz - Chief Executive Officer and President Sriram Ryali - Chief Financial Officer Scott Braunstein - Director Andrew Guggenhime - Director Dara Richardson-Heron - Director Peer Information Caribou Biosciences, Inc. (CORR.) Caribou Biosciences, Inc. (RSPI) Caribou Biosciences, Inc. (CGXP) Caribou Biosciences, Inc. (BGEN) Caribou Biosciences, Inc. (GTBP) Caribou Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 142038108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 99.18 Most Recent Split Date: (:1) Beta: 2.27 Market Capitalization: $208.28 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.33 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.21 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 11.56% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.04 Price/Cash Flow: - Price / Sales: 18.59 EPS Growth vs. Year Ago Period: 39.53% vs. Previous Quarter: 7.14% Sales Growth vs. Year Ago Period: 1.87% vs. Previous Quarter: -39.18% ROE 03/31/26 - -84.17 12/31/25 - -78.40 09/30/25 - -69.85 ROA 03/31/26 - -60.51 12/31/25 - -58.68 09/30/25 - -54.20 Current Ratio 03/31/26 - 6.22 12/31/25 - 5.71 09/30/25 - 5.54 Quick Ratio 03/31/26 - 6.22 12/31/25 - 5.71 09/30/25 - 5.54 Operating Margin 03/31/26 - -999.52 12/31/25 - -1,137.04 09/30/25 - -1,461.90 Net Margin 03/31/26 - -1,189.14 12/31/25 - -1,327.40 09/30/25 - -1,690.45 Pre-Tax Margin 03/31/26 - -1,194.05 12/31/25 - -1,332.33 09/30/25 - -1,690.54 Book Value 03/31/26 - 1.03 12/31/25 - 1.31 09/30/25 - 1.52 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©